Form D · Biotechnology
Virocell Biologics Ltd
London, X0 · CIK 0001948363
Offering snapshot reported Nov 15, 2022 · SEC filing
- Reported sold
- $993K Offering amount: $2.34M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 1, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 15, 2022 | Initial | $992,645 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-464890
There are no finders fees or sales commissions involved
Source: Form D, filed Nov 15, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Todd Christopher Davis | Director |
| J David Enloe Jr. | Director |
| Farzin Farzaneh | Director, Executive |
| John Winthrop Hadden Ii | Director, Executive |
| Peter Eric Priestley | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Vestry House Laurence Pountney Hill
London, X0, EC4 OEH
London, X0, EC4 OEH